Approval · Notice of Compliance 36693 · 2026
APRETUDE: Notice of Compliance 36693
Issued January 7, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36693
- Date
- January 7, 2026
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug product manufacturing site and/or manufacturer involving production
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APRETUDE | Not yet assigned | — |
Medicinal ingredients
- CABOTEGRAVIR 200 MG per ML